TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03201471
Drug: Chidamide + R-CHOP regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
Study: NCT03475680
Drug: Oral Gentamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Study: NCT03475680
Drug: Oral placebo Gentamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1
Study: NCT01966601
Drug: TRV027 Dose #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 continuous intravenous infusion Dose #1
Study: NCT01966601
Drug: TRV027 Dose #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 continuous intravenous infusion Dose #2
Study: NCT01966601
Drug: TRV027 Dose #3
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV027 continuous intravenous infusion Dose #3
Study: NCT01966601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo continuous intravenous infusion
Study: NCT01643083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 2 week
Study: NCT04096742
Drug: tretinoin 0.05% lotion (Altreno)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altreno topical lotion
Study: NCT00887406
Drug: Placebo SD
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose via nebuliser
Study: NCT00887406
Drug: GSK961081 100mcg RD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeat dose via nebuliser
Study: NCT00887406
Drug: GSK961081 300mcg RD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: repeat dose vai nebuliser
Study: NCT00887406
Drug: Placebo RD
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeat dose via nebuliser
Study: NCT02242188
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age.
Study: NCT01903330
Drug: ERC1671
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intradermally
Study: NCT01903330
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
Study: NCT01903330
Drug: Oral Control (Sucrose pill)
Normalized name: Afeditab CR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01862328
Drug: MLN4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle
Study: NCT00467584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
Study: NCT02006147
Drug: TLC399
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
Study: NCT03775265
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03498066
Drug: Continuation of the Betablockers (βB) treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use Betablockers treatment
Study: NCT00547196
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01572961
Drug: acetylsalicilic acids (Aspirin)
Normalized name: ascorbic acid / aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose of 1g.
Study: NCT01572961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02778178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL saline 0.9%, per side
Study: NCT01483872
Drug: NAC/Tigecycline/Heparin combination lock solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02398461
Drug: rHIgM22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via IV infusion
Study: NCT02398461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01394458
Drug: Heparin 1000 u / ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
Study: NCT00215982
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
Study: NCT04345471
Drug: Desvenlafaxine 100 mg
Normalized name: desvenlafaxine 100 MG
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily dosing for 8 weeks
Study: NCT04345471
Drug: Desvenlafaxine 50 mg
Normalized name: desvenlafaxine 50 MG
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily dosing for 8 weeks
Study: NCT04345471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily dosing for 8 weeks
Study: NCT00851045
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution, IV, 400 mg/m2, Q14 days, Until PD
Study: NCT03623256
Drug: Spinal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
Study: NCT00634179
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 mg/m²
Study: NCT00634179
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 750 mg/m²
Study: NCT03804645
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
Study: NCT02260492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose) administered via the Solis dry powder inhaler
Study: NCT00102869
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg levodopa per day over 10 days/ treatment phase
Study: NCT00838877
Drug: radioligand [11C]AZD2184
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of iv admin. 1 time per subject
Study: NCT04203680
Drug: HTK cardioplegic solution
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg
Study: NCT04203680
Drug: blood cardioplegia
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
Study: NCT04324359
Drug: SURF-201
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop twice daily (BID) in the study eye for 16 days.
Study: NCT04324359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop twice daily (BID) in the study eye for 16 days.
Study: NCT00824460
Drug: 1.25 g PA21 (250 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
Study: NCT00824460
Drug: 5.0 g PA21 (1,000 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Study: NCT00824460
Drug: 7.5 g PA21 (1,500 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Study: NCT00824460
Drug: 10.0 g PA21 (2,000 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Study: NCT00824460
Drug: 12.5 g PA21 (2,500 mg iron)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Study: NCT02078063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
Study: NCT02818361
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00920933
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02617758
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
Study: NCT02617758
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
Study: NCT03899259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00225082
Drug: Nucleoside analogue switch
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: stavudine switched to tenofovir
Study: NCT01977430
Drug: Hydrochlorothiazide and furosemide
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
Study: NCT00191906
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, every day (QD), by mouth (PO)
Study: NCT03551730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01411267
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~* 6 mg for patients age \< 1yr~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age
Study: NCT00662688
Drug: Chemotherapy at the investigator's discretion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01152450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: N/A (two actuations of placebo) delivered via Respimat® inhaler
Study: NCT03331341
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04072562
Drug: AZD7594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation.
Study: NCT01756053
Drug: ABT-089
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective neuronal nicotinic receptor agonist.
Study: NCT01756053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsules supplied by study drug supplier.
Study: NCT03470038
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT03038451
Drug: S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02563951
Drug: GNS Spray 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02563951
Drug: GNS Spray 1.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02563951
Drug: GNS Spray 2.0mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01981486
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID modified-release tablets
Study: NCT04530786
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza vaccine 0.5 ml intramuscularly each season, antigens measured for 3 years following vaccination in:~* 2004-2005: A/Wyoming H3N2; B/Shanghai~* 2006-2007: A/New Caledonia H1N1~* 2007-2008: A/Solomon Islands; A/Wisconsin H3N2; B/Malaysia
Study: NCT01617564
Drug: bipuvacain
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
Study: NCT01055249
Drug: Ibuprofen, Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Study: NCT01055249
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
Study: NCT00299182
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, \& 5.
Study: NCT00299182
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,\& 5.
Study: NCT00299182
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 by vein over 2 hours followed by 800 mg/m\^2 over 22 hours Day 2, Cycles 2, 4 \& 6.
Study: NCT00299182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
Study: NCT04138849
Drug: Placebo single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, single dose.
Study: NCT03639701
Drug: Thymidine
Normalized name: Thymidine
DrugBank: Thymidine (DB04485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
Study: NCT00969254
Drug: Pílulas de Lussen
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo.
Study: NCT00969254
Drug: Pyridium®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo.
Study: NCT03229252
Drug: Placebo Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Inhalation Solution
Study: NCT03229252
Drug: SPX-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPX-101 Inhalation Solution
Study: NCT01197378
Drug: Cysteamine Bitartrate Delayed-release Capsules
Normalized name: Cysteamine Bitartrate Delayed-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose.
Study: NCT02008721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01593527
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab 150 mg s.c.
Study: NCT05236946
Drug: Tyrosine kinase inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI
Study: NCT01466803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Study: NCT03136991
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3\&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
Study: NCT03136991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
Study: NCT02058472
Drug: SEVIKAR®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092768
Drug: MK0663, etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092768
Drug: Comparator: celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656773
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
Study: NCT04562610
Drug: Intravenous Infusion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous infusion group will receive two medications via the intravenous infusion route. These medications are Ofirmev ( acetaminophen ) 1,000mg and tranexamic acid 2,000 mg , an antifibrinolytic drug. In addition to these drugs, study subjects will receive Celecoxib 200mg by mouth and Gabapentin 600 mg by mouth prior to operation.
Study: NCT03186729
Drug: Antithrombotic Agent
Normalized name: ANTITHROMBOTIC AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant or antiplatelet drugs
Study: NCT04300855
Drug: Sunphenon
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study agent will be administered in divided doses with food, three capsules twice a day (405 mg) for 24 months
Study: NCT04300855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT04113109
Drug: LCZ 696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
Study: NCT04113109
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle) will be given at the same rate as icatibant.
Study: NCT02039479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as ADD-on to every necessary treatment as usual
Study: NCT00597233
Drug: soluble human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00597233
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00570856
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg/day
Study: NCT00570856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo similar to the folic acid tablets, 1/day
Study: NCT03929666
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally twice daily (PO bid)
Study: NCT03929666
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT00163111
Drug: VFENDÂ® I.V., Oral
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00163111
Drug: Diflucan IV, oral
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04436731
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regional forearm infusion at 8 ng/dL/min via brachial artery catheter during normoxia and hypoxia exposures
Study: NCT03929666
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV